About Biotexuspharma
Biotexuspharma is a company based in India. It operates as a B2B. The company has 15 employees. Biotexuspharma offers products and services including Texcurmin 500 mg Capsule, Texfer 150 mg, Bioplate, and Figtex.
- Headquarter India
- Employees 15
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biotexuspharma.com
- Social LinkedIn X Facebook YouTube
- Legal Name Biotexus Pharmaceutical Pvt. Ltd.
- Date of Incorporation 19 Aug, 2019
- Jurisdiction Kolkata, West Bengal, India
- Annual Revenue₹2.35 Cr
FY 2025 · +8% YoY
- Net Profit₹21.8 Lakh
FY 2025 · 9% margin
- EBITDA₹22.8 Lakh
FY 2025 · 10% margin
- Employee Count15
Associated legal entities of Biotexuspharma
Biotexuspharma operates through Biotexus Pharmaceutical Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Biotexus Pharmaceutical Private Limited CIN U24100WB2019PTC233477 | Active | 19 Aug 2019 | Kolkata, West Bengal | ₹2.3 Cr | 15 | 2 | View details |
Products & Services of Biotexuspharma
Biotexuspharma offers a comprehensive portfolio of products and services, including Texcurmin 500 mg Capsule, Texfer 150 mg, Bioplate, and Figtex.
Capsule used for cancer treatment and supportive care.
Treatment for kidney-related health conditions.
Supplement for general health and wellness support.
Product for nutritional enhancement and daily health.
Apps and channels of Biotexuspharma
its YouTube channel Biotexus has 15 subscribers and 3 videos.
Videos from Biotexuspharma
The most watched videos on Biotexuspharma's YouTube channel, Biotexus (15 subscribers). Click a video to play it here.
More on Biotexus.
Board of directors of Biotexus Pharmaceutical Private Limited (Biotexuspharma)
Biotexus Pharmaceutical Private Limited is the primary company behind Biotexuspharma. The board of Biotexus Pharmaceutical Private Limited currently have 2 directors; the longest-serving is Papiya Maity, appointed in 2019.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Papiya Maity DIN 08539752 | Director | 19 Aug 2019 | 7 yrs 1 mo | Biotexus Pharmaceutical Private Limited |
| Sanat Kumar Maity DIN 06793190 | Director | 19 Aug 2019 | 7 yrs 1 mo | Biotexus Pharmaceutical Private Limited |
Financials of Biotexuspharma
Figures of Biotexus Pharmaceutical Private Limited, the primary company behind Biotexuspharma, for FY 2025. Revenue was ₹2.35 Cr (+8% year on year). Net profit was ₹21.8 Lakh (9% margin). EBITDA was ₹22.8 Lakh (10% margin). Revenue has grown at a compounded annual rate of +35% over three years and +80% over five years.
- ₹2.35 CrRevenue · FY 2025 · +8% YoY
- ₹21.8 LakhNet profit · 9% margin
- ₹22.8 LakhEBITDA · 10% margin
- ₹1 LakhPaid-up capital
- 15Employees (provident fund records)
- +35%Revenue CAGR, 3 years
- +80%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Biotexus Pharmaceutical Private Limited are on its company page.
Detailed financial statements for Biotexuspharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Biotexuspharma
10 companies that operate in the same segment as Biotexuspharma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biotexuspharma
Biotexuspharma is headquartered in India.
Biotexuspharma has 15 employees.
The primary company behind Biotexuspharma, Biotexus Pharmaceutical Private Limited, reported revenue of ₹2.35 Cr for FY 2025, up 8% year on year.
Biotexus Pharmaceutical is a healthcare organization focused on improving lives by offering affordable, high-quality products in oncology, nephrology, general medicine, veterinary care, and nutraceuticals. They emphasize innovation through RD and manufacturing, ensuring accessibility in rural and urban areas of India. Based primarily in Kolkata, they address unmet medical needs via a strong supply chain and partnerships.
Biotexuspharma offers Texcurmin 500 mg Capsule, Texfer 150 mg, Bioplate, and Figtex.
Biotexuspharma operates through Biotexus Pharmaceutical Private Limited.
The legal entities of Biotexuspharma currently have 2 directors, including Papiya Maity, Sanat Kumar Maity.